Distinguished in Wilson Disease

Dr. Mark E. Molitch

Endocrinology
680 N Lake Shore Dr, Suite 1000, 
Chicago, IL 
Distinguished in Wilson Disease
680 N Lake Shore Dr, Suite 1000, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Molitch is an Endocrinologist in Chicago, Illinois. Dr. Molitch is rated as a Distinguished provider by MediFind in the treatment of Wilson Disease. His top areas of expertise are Acromegaloid Facial Appearance Syndrome, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Acromegaly, Hormone Replacement Therapy (HRT), and Parathyroidectomy.

His clinical research consists of co-authoring 162 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 24 articles and participated in 1 clinical trial in the study of Wilson Disease.

Specialties
Endocrinology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

680 N Lake Shore Dr, Suite 1000, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drug: Levoketoconazole
Study Phase: Phase 3
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
Enrollment Status: Completed
Publish Date: December 18, 2024
Intervention Type: Drug
Study Drug: Osilodrostat
Study Phase: Phase 2
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
PERL (Preventing Early Renal Loss in Diabetes) Continuous Glucose Monitoring (CGM) Study
PERL (Preventing Early Renal Loss in Diabetes) Continuous Glucose Monitoring (CGM) Study
Enrollment Status: Completed
Publish Date: March 29, 2022
Intervention Type: Other, Drug
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Enrollment Status: Completed
Publish Date: January 06, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

162 Total Publications

Debate: Surgery as Initial Therapy for Microprolactinoma.
Debate: Surgery as Initial Therapy for Microprolactinoma.
Journal: The Journal of clinical endocrinology and metabolism
Published: June 06, 2025
Similar Doctors
Experienced in Wilson Disease
Dr. Amisha Wallia
Endocrinology
Experienced in Wilson Disease
Dr. Amisha Wallia
Endocrinology

Northwestern Medical Faculty Foundation

1630 Sherman Ave, 
Evanston, IL 
 (11.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amisha Wallia is an Endocrinologist in Evanston, Illinois. Dr. Wallia is rated as an Advanced provider by MediFind in the treatment of Wilson Disease. Her top areas of expertise are Low Blood Sugar, Diabetic Ketoacidosis, Type 2 Diabetes (T2D), and Type 1 Diabetes (T1D).

Experienced in Wilson Disease
Dr. Armand A. Krikorian
Endocrinology
Experienced in Wilson Disease
Dr. Armand A. Krikorian
Endocrinology
4440 W 95th St, 
Oak Lawn, IL 
 (13.3 miles away)
708-684-5646
Languages Spoken:
English
See accepted insurances

Armand Krikorian is an Endocrinologist in Oak Lawn, Illinois. Dr. Krikorian is rated as an Advanced provider by MediFind in the treatment of Wilson Disease. His top areas of expertise are Thyroid Storm, Hypercalcemia, Milk-Alkali Syndrome, and Hypopituitarism.

Experienced in Wilson Disease
Dr. Sandra C. Naaman
Endocrinology
Experienced in Wilson Disease
Dr. Sandra C. Naaman
Endocrinology

Rush University Medical Group

1520 W Harrison St, 
Chicago, IL 
 (2.3 miles away)
312-942-5904
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sandra Naaman is an Endocrinologist in Chicago, Illinois. Dr. Naaman is rated as an Experienced provider by MediFind in the treatment of Wilson Disease. Her top areas of expertise are Postmenopausal Osteoporosis, Osteoporosis, Wilson Disease, and Diabetic Nephropathy. Dr. Naaman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Molitch's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 14 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile